Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

Rhea-AI Summary

Allurion Technologies (NYSE: ALUR) published new data showing that patients on the Allurion Program gained an average of 5.6% lean mass while losing 14% body weight over four months. The study included 571 patients tracked using the Allurion App, Connected Scale, and Health Tracker, supported by the AI-driven Allurion Virtual Care Suite. On average, patients reduced their weight from 97.9kg to 84.0kg and increased lean mass from 49.8kg to 52.6kg. Higher activity patients achieved a greater weight loss (15.6kg) and more significant lean mass gains (2.8kg) compared to lower activity patients. The body fat percentage also decreased from 32.7% to 27.9%. This study contrasts with GLP-1 therapy results, which typically show lean mass loss ranging from 3-11%, highlighting the potential of real-time body composition monitoring and personalized recommendations.

Positive

• Patients on the Allurion Program gained an average of 5.6% lean mass.
• Patients experienced an average weight loss of 14% in four months.
• Higher activity patients achieved a greater weight loss of 15.6kg and lean mass gain of 2.8kg.
• Body fat percentage decreased significantly from 32.7% to 27.9%.
• The program showcases the benefits of real-time body composition monitoring and AI-driven personalized care.

Negative

• None.

Insights

Medical Research Analyst

The new data from Allurion Technologies offers promising insights into the relationship between weight loss and lean mass preservation. The study encompassed 571 patients and showed an average weight loss of 13.9kg over four months, with a significant lean mass gain of 5.6%. This contrasts sharply with previous studies on GLP-1 therapies, where lean mass losses of up to 11% were observed.

Tracking vital signs and physical activity in real-time through the Allurion App and AI-powered Virtual Care Suite is a game-changer. Real-time data allows for personalized adjustments to diet and exercise regimes, potentially explaining the lean mass gains. For retail investors, this suggests a potentially higher efficacy and appeal of the Allurion Program compared to traditional GLP-1 therapies.

However, it's important to note the relatively short duration of four months in this study. Long-term efficacy and potential adverse effects remain to be seen, which could impact investor sentiment positively or negatively based on future results.

Financial Analyst

Allurion Technologies' recent data publication could have significant market implications. The company, listed on NYSE, demonstrated not only effective weight loss but also an increase in lean mass—a point of differentiation from competitors using GLP-1 therapies. This unique value proposition could attract a broader customer base and justify a premium pricing model, potentially boosting revenue and profitability.

From a financial perspective, the real-time tracking and AI-powered insights add a tech-driven edge to Allurion's offerings. Investors should keep an eye on how well this technology scales and whether it continues to produce similar outcomes in larger, more diverse populations. Additionally, the success of their AI module could open new revenue streams through data licensing or partnerships.

Future earnings reports will need to reflect this potential. If the company can demonstrate sustained growth and adoption rates, the stock could see upward momentum.

Patients gained an average of 5.6% in lean body mass during the Allurion Program

Separate studies of patients on GLP-1 therapy report an average lean mass loss of 11%¹

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite.

In the study, 571 patients across three obesity centers treated with the Allurion Program reduced their weight on average by 13.9kg from 97.9kg to 84.0kg in just four months. Over that same period, lean mass—which includes muscle mass—increased by 2.8kg on average from 49.8kg to 52.6kg.

Higher activity patients, walking more than 8,000 daily steps on average, achieved higher weight loss (15.6kg on average, from 97.7kg to 82.1kg) and gained more lean mass (increased by 2.8kg on average from 50.9kg to 53.7kg) than their lower activity counterparts who achieved a weight loss of 13.6kg on average, from 98.2kg to 84.6kg, and whose lean mass increased by 1.8kg on average, from 49.5 to 51.3kg.

All patients experienced significant reductions in body fat percentage, decreasing from 32.7% to 27.9% in just 4 months.

Previous studies evaluating body composition changes in patients treated with GLP-1s have demonstrated that lean body mass losses are common, ranging from 3-11% lean mass reductions after around a year of treatment. Importantly, these studies did not incorporate any real-time monitoring of body composition or personalized approaches to promote lean mass preservation or muscle mass gain.^1,2

“Historically, weight loss has come at the expense of lean muscle mass, the maintenance of which is critical to overall health. These results demonstrate just the opposite, providing evidence that it is possible to lose significant amounts of weight while maintaining, and even increasing, lean body mass,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We believe that this data underscores the impact of real-time monitoring of body composition and personalized recommendations through our AI-powered Virtual Care Suite. In fact, we believe that using Allurion’s AI platform with other modalities—including GLP-1s, where muscle mass loss is a significant risk—may be a promising path forward.”

Sources: 1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. 2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, including the VCS, to improve patient and clinical outcomes, including outcome improvements over time, the impact of a behavior change coaching skills course, and the impact of gLP-1s on the Allurion Program. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620790388/en/

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor Contact

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

FAQ

What is the average lean mass gain reported in Allurion's latest study?

The average lean mass gain reported is 5.6%.

How much weight did patients lose on average in the Allurion Program?

Patients lost an average of 14% of their body weight.

What is the stock symbol for Allurion Technologies?

The stock symbol for Allurion Technologies is ALUR.

How does the Allurion Program compare to GLP-1 therapy in terms of lean mass?

Unlike GLP-1 therapy, which shows lean mass losses of 3-11%, the Allurion Program results in an average lean mass gain of 5.6%.

What tools are used to track patient progress in the Allurion Program?

Patient progress is tracked using the Allurion App, Connected Scale, and Health Tracker.

What was the average body fat percentage reduction in the Allurion Program?

The average body fat percentage decreased from 32.7% to 27.9%.